**Company Overview**

CohBar (NASDAQ:CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar’s efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases, including obesity, nonalcoholic steatohepatitis (NASH), Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the Company and its founders have discovered more than 100 MDPs.

---

**Management Team**

- **Philippe P. Calais, Pharm. D., Ph.D.**
  Chief Executive Officer

- **Kenneth C. Cundy, Ph.D.**
  Chief Scientific Officer

- **Jeffrey F. Biunno, CPA, MBA**
  Chief Financial Officer, Secretary and Treasurer

- **Jon L. Stern, MBA**
  Chief Operating Officer, Director

---

**CohBar, Inc.**

1455 Adams Drive
Suite 2050
Menlo Park, CA 94025

---

**Stock Overview**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>CWBR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exchange</td>
<td>Nasdaq</td>
</tr>
<tr>
<td>Market Cap</td>
<td>$95.89m</td>
</tr>
<tr>
<td>Last Price</td>
<td>$2.40</td>
</tr>
<tr>
<td>52-Week</td>
<td>$2.11 - $10.789</td>
</tr>
</tbody>
</table>

05/02/2019 04:00 PM EDT

---

**Disclaimer**

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.